JAK Inhibitors Raise New Safety Questions
Rheumatologists increasingly prescribe JAK inhibitors for rheumatoid arthritis and other immune diseases. These oral drugs offer convenience over injectables. Recent global trials flagged cardiovascular risks with JAK-Is compared to TNF inhibitors. Korean doctors now have local data to guide choices. This study published in the Cardiology digs into real-world adverse event reports carefully.
National Database Tracks Real-World Reports
Researchers pulled data from Korea Adverse Event Reporting System database from January 1, 2015 to December 31, 2020. They focused on tofacitinib and baricitinib as JAK-Is. TNF-Is included adalimumab, etanercept, and golimumab. Total reports reached 625 for JAK-Is and 4,777 for TNF-Is. Drug-AE pairs numbered 876 for JAK-Is and 7,999 for TNF-Is after analysis.
Cardiovascular Events Show Strong Signals
Disproportionality analysis used reporting odds ratios with 95% confidence intervals from 2x2 tables. JAK-Is showed higher CVE reporting than TNF-Is with ROR 4.90 and 95% CI 2.80-8.59. Major cardiovascular events, thrombosis, and other CVEs all contributed to the signal. Thrombosis stood out strongest at ROR 12.70 with 95% CI 5.10-31.66. These findings align with international concerns about JAK-I safety.
Women and Older Patients at Highest Risk
Signals proved strongest in women with CVE ROR 7.52 and 95% CI 3.06-18.47. Patients over 50 years showed CVE ROR 5.01 with 95% CI 2.02-12.43. Age and sex patterns match ORAL Surveillance trial results. Rheumatologists must weigh these risks against RA control benefits carefully.
Thrombosis Signal Demands Attention
Thrombosis ROR of 12.70 signals urgent need for monitoring. JAK-Is block multiple cytokines, possibly affecting clotting pathways differently than TNF-Is. Baseline CV risk assessment becomes essential before starting therapy. Smoking cessation and statin use may mitigate risks in high-risk patients.
Clinical Implications for Daily Practice
Choose TNF-Is first in RA patients with CV history or risk factors. Reserve JAK-Is for TNF failures after shared decision-making. Screen for thrombosis risk at baseline and follow closely. Report adverse events to KAERS to build better data. Guidelines may shift based on accumulating evidence like this.
Balance Efficacy Against Emerging Risks
JAK-Is transform RA treatment with rapid onset and oral dosing. Safety signals remind us no drug lacks risks. Korean data strengthens global warnings for careful patient selection.